Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
Launched by CHILDREN'S ONCOLOGY GROUP · May 25, 2004
Trial Information
Current as of July 30, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES: I. Modify chemotherapy courses based on initial response to therapy in children with newly diagnosed stage IA/IIA/IIIA1 Hodgkin's disease. II. Examine the activity of variable courses of doxorubicin, bleomycin, vincristine, and etoposide (DBVE) followed by low-dose involved-field irradiation in these patients. III. Monitor the safety and feasibility of the response-dependent approach and the morbidity and immediate and long-term toxic effects associated with this regimen. IV. Assess whether limited therapy is adequate for patients with an early response. V. Evaluate whether the ...
Gender
ALL
Eligibility criteria
- • DISEASE CHARACTERISTICS: Histologically proven Hodgkin's disease No more than 5 weeks since diagnostic biopsy No B symptoms Clinical/pathologic stages (all histologies) as follows: Stage IA/IIA with mediastinal mass less than one third of chest diameter Stage IIIA limited to spleen or splenic, celiac, or portal nodes and lesions no larger than 6 cm Surgical staging required if: Clinical and imaging findings equivocal Tanner stage IV/V for whom radiotherapy is planned Concurrent registration on protocols POG-8828 (late effects study) and POG- 8829 (epidemiology study) required
- • PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified Hematopoietic: No hematopoietic disease Hepatic: No liver disease Renal: No renal disease Other: No severe organ or system damage or failure No pregnant or nursing women
- • PRIOR CONCURRENT THERAPY: No prior therapy
About Children's Oncology Group
The Children's Oncology Group (COG) is a leading national organization dedicated to improving the care and outcomes of children with cancer through collaborative research and clinical trials. Comprising a network of pediatric oncology experts, COG focuses on developing innovative treatment protocols, advancing scientific knowledge, and enhancing the quality of life for young patients. By fostering interdisciplinary collaboration and utilizing a comprehensive approach to childhood cancer, COG aims to translate research findings into effective therapies, ultimately striving for a cure for all children diagnosed with cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Seattle, Washington, United States
New York, New York, United States
Houston, Texas, United States
Ann Arbor, Michigan, United States
New York, New York, United States
Rochester, Minnesota, United States
Los Angeles, California, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Iowa City, Iowa, United States
Minneapolis, Minnesota, United States
Chapel Hill, North Carolina, United States
Cleveland, Ohio, United States
San Francisco, California, United States
Kalamazoo, Michigan, United States
Nashville, Tennessee, United States
Fargo, North Dakota, United States
Travis Air Force Base, California, United States
Madison, Wisconsin, United States
New York, New York, United States
Salt Lake City, Utah, United States
Fargo, North Dakota, United States
New Brunswick, New Jersey, United States
Omaha, Nebraska, United States
Long Beach, California, United States
Los Angeles, California, United States
Orange, California, United States
Denver, Colorado, United States
Washington, District Of Columbia, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Portland, Oregon, United States
Pittsburgh, Pennsylvania, United States
Seattle, Washington, United States
Perth, Western Australia, Australia
Vancouver, British Columbia, Canada
Halifax, Nova Scotia, Canada
Kansas City, Missouri, United States
Patients applied
Trial Officials
Cameron K. Tebbi, MD
Study Chair
St. Joseph's Children's Hospital of Tampa
Michael A. Weiner, MD
Study Chair
Herbert Irving Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials